W
Waker Biology
Safety assessment services for cell and gene therapy
About Waker Biology
Waker Bioscience provides safety assessment services for cell and gene therapy drug products. The company specializes in insertion mutation risk assessment, quantitative off-target analysis for CRISPR/Cas9, and sgRNA screening. Their services cater to pharmaceutical clients, aiming to help them develop novel cell and gene therapies that meet regulatory safety standards. The service portfolio includes Integration Site Analysis, On-/Off-Target Analysis, Vector Copy Number, and Vector Quality Control.
Operating under GLP regulations, Waker Bioscience has an 800-square-meter laboratory and has established an advanced genomics and bioinformatics platform. The company's core technologies, S-EPTS/LM PCR and TES systems, originated from Manfred Schmidt's team at the German National Cancer Center. Waker Bioscience reports having participated in over 130 gene therapy projects globally and completed insertion mutation risk assessments for more than 50 clinical trials. They offer customized services that cover the entire process from sample receipt and quality control to library preparation, next-generation sequencing, bioinformatics analysis, and providing ISA risk assessment reports.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biomarkers, Genetics and genomics, Crispr, Gene Therapy, Techbio, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2025 | $14M | $55M | Wuxi Innovation Investment Group · Shenzhen Capital Group | ↗ |
| ANGELEquity / VC | Dec 2022 | $0 | — | BGI Co-Win | ↗ |
Growth signals
Latest recorded traffic for Waker Biology is 1.1K monthly website visits, up 129.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
BGI Co-Win
Series A2 investors entered at this stage
Shenzhen Capital Group
Wuxi Innovation Investment Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Waker Biology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Waker Biology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.